Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies

Abstract

Background: In the past decade, there have been significant breakthroughs in immunotherapies for B-cell lymphoid malignancies and multiple myeloma, but progress has been much less for acute myeloid leukemia (AML). Nevertheless, challenge begets innovation and several therapeutic strategies are under investigation. Summary: In this review, we review the state of the art in AML immunotherapy including CD33-and CD123-Targeted agents, immune checkpoint inhibition, and adoptive cell therapy strategies. We also share conceptual frameworks for approaching the growing catalog of investigational AML immunotherapies and propose future directions for the field. Key Messages: Immunotherapies for AML face significant challenges but novel strategies are in development.